(0.13%) 5 187.70 points
(0.08%) 38 884 points
(-0.10%) 16 333 points
(-0.14%) $78.37
(1.09%) $2.22
(-0.37%) $2 322.50
(-0.49%) $27.48
(2.39%) $988.00
(0.17%) $0.930
(0.73%) $10.90
(0.44%) $0.799
(0.11%) $91.45
Quarter results tomorrow
(amc 2024-05-08)
Expected move: +/- 6.23%
-6.87% $ 4.07
Live Chart Being Loaded With Signals
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer...
Stats | |
---|---|
Volumen de hoy | 4.25M |
Volumen promedio | 4.85M |
Capitalización de mercado | 277.32M |
EPS | $0 ( 2024-03-11 ) |
Próxima fecha de ganancias | ( $-0.0300 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -407.00 |
ATR14 | $0.0180 (0.44%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-26 | Mccarthy Sean A. | Buy | 109 768 | Common Stock |
2024-03-26 | Mccarthy Sean A. | Sell | 109 768 | Stock Option (Right to Buy) |
2024-03-20 | Su Zhen | Buy | 76 000 | Stock Option (Right to Buy) |
2024-03-20 | Su Zhen | Buy | 0 | |
2024-03-19 | Rowland Lloyd A | Sell | 5 268 | Common Stock |
INSIDER POWER |
---|
64.88 |
Last 98 transactions |
Buy: 4 891 928 | Sell: 1 103 909 |
Volumen Correlación
CytomX Therapeutics Inc Correlación
10 Correlaciones Más Positivas | |
---|---|
GURE | 0.925 |
EYEG | 0.922 |
DIBS | 0.919 |
SWVL | 0.918 |
EIGR | 0.917 |
JOAN | 0.917 |
AFIB | 0.916 |
LPSN | 0.913 |
QRTEA | 0.912 |
RUBY | 0.911 |
10 Correlaciones Más Negativas | |
---|---|
SGEN | -0.906 |
GETVV | -0.903 |
STAY | -0.894 |
PUCKU | -0.887 |
TVTY | -0.886 |
CCRC | -0.886 |
DSPG | -0.884 |
ALTR | -0.875 |
SNCR | -0.875 |
MTEK | -0.873 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
CytomX Therapeutics Inc Correlación - Moneda/Commodity
CytomX Therapeutics Inc Finanzas
Annual | 2023 |
Ingresos: | $101.21M |
Beneficio Bruto: | $99.04M (97.85 %) |
EPS: | $-0.00770 |
FY | 2023 |
Ingresos: | $101.21M |
Beneficio Bruto: | $99.04M (97.85 %) |
EPS: | $-0.00770 |
FY | 2022 |
Ingresos: | $53.16M |
Beneficio Bruto: | $47.31M (88.98 %) |
EPS: | $-1.480 |
FY | 2021 |
Ingresos: | $69.57M |
Beneficio Bruto: | $69.57M (100.00 %) |
EPS: | $-1.300 |
Financial Reports:
No articles found.
CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico